PMC:7283670 / 67382-67888 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T234","span":{"begin":437,"end":441},"obj":"Body_part"}],"attributes":[{"id":"A234","pred":"fma_id","subj":"T234","obj":"http://purl.org/sig/ont/fma/fma256135"}],"text":"Tetrandrine tablets used in the treatment of COVID‐19 Drug: tetrandrine China/COVID‐19 60, all, 18–75 Treatment Experimental: tetrandrine cohort after the subjects were enrolled, they were given “Tetrandrine 60 mg QD” for a course of 1 week (take 6 days, stop using for 1 day)\nNo intervention: control cohort treatment according to standard protocols without intervention IV Primary (12 weeks): survival rate secondary (2 weeks): body temperature NCT04308317/Enrolling by invitation, Mar5‐May1 2020"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T379","span":{"begin":45,"end":53},"obj":"Disease"},{"id":"T380","span":{"begin":80,"end":88},"obj":"Disease"}],"attributes":[{"id":"A379","pred":"mondo_id","subj":"T379","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A380","pred":"mondo_id","subj":"T380","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Tetrandrine tablets used in the treatment of COVID‐19 Drug: tetrandrine China/COVID‐19 60, all, 18–75 Treatment Experimental: tetrandrine cohort after the subjects were enrolled, they were given “Tetrandrine 60 mg QD” for a course of 1 week (take 6 days, stop using for 1 day)\nNo intervention: control cohort treatment according to standard protocols without intervention IV Primary (12 weeks): survival rate secondary (2 weeks): body temperature NCT04308317/Enrolling by invitation, Mar5‐May1 2020"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T599","span":{"begin":99,"end":101},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T600","span":{"begin":227,"end":228},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"Tetrandrine tablets used in the treatment of COVID‐19 Drug: tetrandrine China/COVID‐19 60, all, 18–75 Treatment Experimental: tetrandrine cohort after the subjects were enrolled, they were given “Tetrandrine 60 mg QD” for a course of 1 week (take 6 days, stop using for 1 day)\nNo intervention: control cohort treatment according to standard protocols without intervention IV Primary (12 weeks): survival rate secondary (2 weeks): body temperature NCT04308317/Enrolling by invitation, Mar5‐May1 2020"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T218","span":{"begin":0,"end":11},"obj":"Chemical"},{"id":"T219","span":{"begin":201,"end":212},"obj":"Chemical"},{"id":"T220","span":{"begin":219,"end":221},"obj":"Chemical"},{"id":"T221","span":{"begin":378,"end":380},"obj":"Chemical"}],"attributes":[{"id":"A218","pred":"chebi_id","subj":"T218","obj":"http://purl.obolibrary.org/obo/CHEBI_49"},{"id":"A219","pred":"chebi_id","subj":"T219","obj":"http://purl.obolibrary.org/obo/CHEBI_49"},{"id":"A220","pred":"chebi_id","subj":"T220","obj":"http://purl.obolibrary.org/obo/CHEBI_50853"},{"id":"A221","pred":"chebi_id","subj":"T221","obj":"http://purl.obolibrary.org/obo/CHEBI_74327"}],"text":"Tetrandrine tablets used in the treatment of COVID‐19 Drug: tetrandrine China/COVID‐19 60, all, 18–75 Treatment Experimental: tetrandrine cohort after the subjects were enrolled, they were given “Tetrandrine 60 mg QD” for a course of 1 week (take 6 days, stop using for 1 day)\nNo intervention: control cohort treatment according to standard protocols without intervention IV Primary (12 weeks): survival rate secondary (2 weeks): body temperature NCT04308317/Enrolling by invitation, Mar5‐May1 2020"}

{"project":"LitCovid-sentences","denotations":[{"id":"T658","span":{"begin":0,"end":281},"obj":"Sentence"},{"id":"T659","span":{"begin":282,"end":506},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Tetrandrine tablets used in the treatment of COVID‐19 Drug: tetrandrine China/COVID‐19 60, all, 18–75 Treatment Experimental: tetrandrine cohort after the subjects were enrolled, they were given “Tetrandrine 60 mg QD” for a course of 1 week (take 6 days, stop using for 1 day)\nNo intervention: control cohort treatment according to standard protocols without intervention IV Primary (12 weeks): survival rate secondary (2 weeks): body temperature NCT04308317/Enrolling by invitation, Mar5‐May1 2020"}